Home / Transcripts / Arcutis Biotherapeutics, Inc. (ARQT) · November 4, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Earnings Call Transcript

November 4, 2026

NASDAQ US Health Care Biotechnology earnings 75 min

Earnings Call Speaker Segments

Brian Szalkowski executive
#1

Thanks, Michelle. Good afternoon, everyone, and I appreciate you being with us today as we go over the financial results and business update for our third quarter of 2026. The slides for today's call can be found in the Investors section of the Arcutis website. On the call with me today are Frank Watanabe, Arcutis's President and CEO; Rob Lisicky, our Chief Commercial Officer; Patrick Burnett, our Chief Medical Officer; and Latha Vairavan, our Chief Financial Officer. I'd like to remind everyone that during this call we will be making forward-looking statements. Such statements carry certain risks and uncertainties, and actual results could differ. We encourage you to review all of the company's filings with the Securities and Exchange Commission, including the descriptions of our business and risk factors. With that, I'll hand the call over to Frank to get today's call started.

Frank Watanabe executive
#2

Thanks, Brian, and good afternoon to all of you. We're always glad to have you with us on this quarterly update call. It's difficult to believe that 2026's fourth and final quarter is already here. To start this afternoon, I'll go over the business and what we accomplished during the third quarter, as we continue to carry out our Grow, Expand, and Build corporate strategy and keep delivering on our mission of bringing meaningful innovation to people living with chronic inflammatory skin diseases. I'll then take a couple of minutes to discuss a question that has come up often lately — specifically, how we approach applying artificial intelligence at Arcutis. Following that, I'll hand things over to Rob for a commercial update. After that, Patrick will walk you through where things stand with our R&D programs and initiatives, and Latha will wrap up with a look at the quarter's financial results before we take your questions. I'm on slide 5. It's now been a year since we introduced our three-pillar Grow, Expand, and Build strategy, which is meant to support both near- and long-term corporate growth, and once again in the third quarter we delivered meaningful progress on all three pillars. I'll begin with the Grow pillar, which covers the work aimed at reinforcing our core Zoryve business in the three indications we currently have: plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Toward the end of September, we shared news of a very exciting new collaboration with Simone Biles, the world champion gymnast, to kick off our Skin to Believe In awareness campaign. This wide-ranging, multichannel effort aims to get the roughly 36 million Americans who have eczema or seborrheic dermatitis to speak with their doctors about topical treatments that are long-term and steroid-free for their chronic skin conditions. As part of the campaign, Simone will talk about her own journey of living with and managing her seborrheic dermatitis and eczema, and she'll also discuss her experience with Zoryve foam and cream. Partnering with Simone, among the most recognized and well-respected athletes anywhere in the world, is a genuine honor for us. Simone genuinely and reliably champions health and wellness causes, which makes her an exceptionally influential representative for our brand. Through telling the story of what she faces in living with these skin conditions, Simone will surely inspire others to seize command of their skin health by consulting their healthcare provider about sophisticated non-steroidal therapies such as Zoryve. This awareness effort carries significance on its own, and it also dovetails with our broader commercial programs, including virtual health and the primary care and pediatric sales force we have been deploying across the course of the year. Taken together, these efforts are meant to build recognition of Zoryve's distinctive therapeutic profile on the part of clinicians and patients alike, and afterward to make it easy for patients to obtain Zoryve once it has been determined to be the right therapeutic option. Across all such programs, we are reinvesting the cash Zoryve brings in back into the franchise, allowing us to pursue lasting growth and a genuine inflection in sales by 2027. And under the Grow pillar, we are truly excited to report that we are launching a new trial of Zoryve cream 0.3% in moderate-to-severe atopic dermatitis. Clinicians already rely on Zoryve cream 0.15% as a meaningful option when treating mild-to-moderate atopic dermatitis, and the purpose of this study, which Patrick will walk through shortly, is to assess Zoryve in those more severe patients, who need treatments that are just as effective and well tolerated for managing their chronic inflammatory skin disease as patients with less severe disease get. We are also looking forward eagerly to the February 2027 PDUFA date for Zoryve cream 0.05% for mild-to-moderate atopic dermatitis in infants 3 to 24 months old, and launch preparations are already in motion. This broader indication will rest on the strength of data from our Phase 2 INTEGUMENT-INFANT trial. We're genuinely enthusiastic about the possibility of providing this infant population—and the people who look after them—with an effective topical treatment that isn't a steroid, one that's safe to apply anywhere on the body and for however long it's needed. Clinicians are awaiting this potential indication with tremendous eagerness, because at present they truly wrestle with too few adequate options when treating these most vulnerable patients. These clinical investments in our inline Zoryve business will further reinforce the franchise's medium-term growth, and so will the money we're putting into exploring possible expansions of the indication. Moving on to the Expand pillar, where we keep working toward possibly broadening Zoryve's reach to patients whose needs aren't yet met across various other inflammatory skin conditions — a path informed by the large, persuasive body of case reports on Zoryve. As we've said before, the Phase 2 proof-of-concept vitiligo trial has now finished enrolling. We're still on track to share results from that vitiligo study during Q4 of this year, and alongside them a call on whether those findings justify advancing the program. Screening and enrollment are ongoing for the Phase 2 proof-of-concept studies in hidradenitis suppurativa, or HS, and we anticipate a readout for the HS program around the same point, late in Q1 of 2027. There's also a new study we're really looking forward to that's just getting started. It will evaluate Zoryve for the debilitating skin rashes that affect up to half of all patients on life-saving checkpoint inhibitor therapies like Keytruda and Opdivo. Strange as it sounds, those rashes are actually a sign the treatment is working, but they frequently lead patients to reduce or even halt their therapy. Something with a favorable safety and efficacy profile for these common side effects would be well received. We continue to look at other potential indications and anticipate announcing additional Phase 2 POC studies in the quarters ahead. In the branded non-steroidal topical category, the scope and aspiration of what we're pursuing clinically with Zoryve remain without equal. Those efforts are made possible by Zoryve's differentiated therapeutic profile along with its pleiotropic mechanism of action, which is distinct. And we're moving these forward while awareness keeps rising about the harmful side effects that come from extended or inappropriate corticosteroid use, and while a growing push exists to move the standard of care toward advanced non-steroidal treatments. Put simply, our belief is that the timing is right, the place is right, and the drug is right. Finally, I'll address the Build pillar and discuss how we're working to expand our innovative pipeline beyond Zoryve. Progress is ongoing in the Phase 1a/1b study of ARQ-234, our novel biologic targeting CD200R that may serve as a treatment for moderate-to-severe atopic dermatitis. Additionally, as mentioned on prior calls, we anticipate that external innovation will play a major role in our efforts to grow the pipeline. Keeping that in mind, we continue to actively evaluate a range of external assets. Throughout dermatology and the neighboring I&I space, there is a considerable amount of emerging scientific and therapeutic innovation, and the potential opportunities to make a difference are extensive and very exciting. Lastly, as Latha will detail, from a financial standpoint we posted another robust quarter. The sustained performance level throughout our core Zoryve business, together with the cash flow it produces, is letting us keep investing in innovation and is securing the foundation for Arcutis's long-term success.

Frank Watanabe executive
#3

During our Q2 call, you may remember we raised 2026 full-year net revenue guidance by $45 million at the midpoint, to a range of $525 to $540 million, factoring in our strategic investment portfolio and the ongoing strength of our core business. Given the visibility we have into the rest of the year and how strong our Q3 results have been, we're raising that range again today, to between $535 and $545 million. Before I walk through the quarter's results, I want to take a moment to address a question we keep getting more and more often — I'm on slide 6 now — and that's how we're approaching AI adoption at Arcutis. Everyone can see that artificial intelligence is making, and will keep making, a meaningful impact on biotech, much as it is across virtually every other area of business. As I've said before, if the only tool you have is a hammer, everything starts to look like a nail. In our view, there's a risk that plenty of companies will overspend on AI initiatives that deliver little or no tangible benefit to their customers and shareholders. At Arcutis, our approach to harnessing AI in the business is measured and intentional. We recognize the potential, but we stay very thoughtful about when we deploy it, and equally about how we safeguard our data — a critical matter in a knowledge-intensive field such as biotech. Our disciplined approach starts with assessing when and where AI can accelerate our business. A central question must be whether AI provides distinct advantages relative to other traditional approaches. Where AI makes sense, we aim to pursue those projects with the biggest impact on our highest-priority business objectives. Any AI project must demonstrate measurable value and the potential for a high return on investment. Finally, and crucially, we examine every potential AI project closely to make sure we can protect our proprietary data and information. Through this disciplined approach, we've already identified over 30 discrete AI use cases across the business, some already deployed and many others now in the production phase. For instance, we recently equipped our field sales team with an industry-leading, AI-enabled toolkit that helps them harness all the information available to us to better analyze their business, prioritize which clinicians to call on, which clinical data may be most relevant for the clinicians they engage with, and how best to present Zoryve materials. These efforts are already delivering a positive impact and becoming an important part of our reps' toolkit. Rob, Patrick, and I were out in the field with our team last week, and we were impressed by how quickly our team is leveraging these new tools to boost their effectiveness. We're also partnering with companies that deploy AI-enabled prescription workflow platforms to streamline the post-prescription process for medical offices, as we've described before, which supports a smoother and more efficient path for patients to receive their Zoryve prescriptions once they're written. Not long ago, our medical affairs group and our IT team worked together to apply AI in reviewing over 30 million FDA safety reports along with more than 1,000 FDA product labels, aiming to make clearer just how much a revision of topical steroid labeling is needed. That work produced a significant publication in a peer-reviewed journal, and it is helping to build the groundwork for regulatory action concerning topical steroids. One last illustration: our finance team has been using several AI-enabled tools to boost both efficiency and accuracy in key business processes, including accounts receivable. Given the early success we have seen from these considered AI implementations across our business, we will keep pursuing measured and deliberate AI deployments. This is simply the newest instance of meaningful innovation at the core of what we do here at Arcutis. Now, before going further, I want to share news that is, for me, very exciting both personally and for the Arcutis team. Today I am pleased to announce that Rob Lisicky has agreed to remain with us permanently in the role of Chief Commercial Officer. As I noted on our Q2 call, Rob carries a wealth of experience directing best-in-class commercial teams within the inflammation and immunology space and in generating rapid sales growth to build blockbuster franchises. Rob and I have known one another for, gosh, over two decades, going back to when we worked together on Enbrel, and I can say unreservedly that he ranks among the finest commercial leaders I have ever been privileged to work alongside during my years in this industry. As one would expect, Rob has moved into the CCO role seamlessly and already has a solid grasp of our strategic vision along with the near- and long-term plans for Zoryve. He is delivering a meaningful impact as we keep executing in 2026 and get ready for a very busy 2027. The leadership, commercial savvy, and drive Rob contributes are perfectly suited to where we stand right now with Zoryve, and I cannot imagine a better person to take Zoryve to its full blockbuster potential. With that, I will now turn things over to Rob for his opening commentary on the business and the third quarter commercial results.

Rob Lisicky executive
#4

unclear Frank for the unclear

Frank Watanabe executive
#5

Rob, Rob, your audio is breaking up a little bit.

Rob Lisicky executive
#6

Really? unclear

Frank Watanabe executive
#7

Rob, I think folks are having a hard time hearing you.

Rob Lisicky executive
#8

Excited unclear

Frank Watanabe executive
#9

It looks like Rob is running into a few technical problems, so while we get those sorted out, perhaps I'll jump in here and — not clear

Rob Lisicky executive
#10

Can you hear me?

Frank Watanabe executive
#11

You're coming in and out, Rob.

Rob Lisicky executive
#12

Sorry about that, folks. Everything came through clean on our end. I'll take another shot at this — and if anything I say isn't clear, Frank or the team, just flag it for me.

Frank Watanabe executive
#13

Actually, Rob, that's better.

Rob Lisicky executive
#14

Great. It's a pleasure to be on today's call, and I'm genuinely thrilled to be part of this Arcutis team that's so focused on its mission and driven by results. First, I'd like to thank Frank for <<inaudible>> and the board too for giving me this chance. As Frank said, the two of us have known each other for decades; from my standpoint, watching Arcutis climb steadily into the role of a next-generation leader in chronic inflammatory skin disease has been deeply satisfying. Now it's a privilege to actually be part of that and to head the commercial organization, which has been built on such a firm and solid foundation. If you'll allow me, I'd like to offer a few brief first impressions from my time in the role so far. First, the momentum, growth, and opportunities for Zoryve, the franchise, are truly extraordinary, given its unquestioned leadership of the growing branded topical non-steroidal segment while the aging topical corticosteroid class is steadily being displaced by newer, more innovative options. From my years in the industry, I know the phrase paradigm shift gets used very often, but for the millions of people affected by chronic inflammatory skin conditions, often for decades, and in need of topical treatments, a product like Zoryve that delivers efficacy yet can be used anywhere, on any part of the body, for any duration of time, truly does embody a paradigm shift. The market share Zoryve has captured so far, in my view, is merely the tip of the iceberg. Building on what Frank said earlier, we believe Arcutis is indeed in the right place, at the right time, with the right drug, and I would add, with the right team. During my time here, I have found this to be a deeply experienced, talented, and dedicated group of people operating at the highest level, with an unwavering dedication to helping patients. Moving to slide 8, and turning to commercial results for the quarter, we continue to see robust sales performance and demand-driven growth in the third quarter. Net product revenue was <<inaudible>> 143.9 million, which represents a 45% <<inaudible>> 25, <<inaudible>> this <<inaudible>> Zoryve...

Frank Watanabe executive
#15

Rob? Rob — sorry, we've lost you once more. It seems like we'll have to attempt a different approach. Perhaps I should step in briefly while Rob gets his audio problems sorted out.

Rob Lisicky executive
#16

...was primarily unclear

Frank Watanabe executive
#17

We're still on slide 8. As Rob, I believe, was mentioning — hopefully you all caught it, and apologies that Murphy is tagging along with us today — we saw genuinely strong sales results and growth driven by demand during the third quarter. Net product revenues came in at $143.9 million, which works out to a 45% rise compared with the third quarter of 2025 and an 11% gain versus Q2 of this year.

Rob Lisicky executive
#18

Frank, I’ve just rejoined. Something on the system is muting me, apparently. You have my apologies.

Frank Watanabe executive
#19

Great.

Rob Lisicky executive
#20

To build on what Frank said, the fact that demand kept rising even with the usual Q3 seasonal headwinds really shows the strength of this franchise. What matters is that during the period we saw demand increase across every indication and every formulation. As we anticipated, our gross-to-net rate improved only slightly versus the second quarter, and lower copay expense was the main reason for that. On the whole, GTN is holding steady in the low 50s. Turning to the fourth quarter, we anticipate considerable sequential demand growth, driven by the momentum of our base business drivers, by the ongoing conversion of topical corticosteroids to branded non-steroidal treatment options, and by the effect of the many commercial initiatives we are funding to speed up Zoryve's growth; we also anticipate that demand growth will get support from the usual fourth-quarter seasonality tailwinds, and we anticipate gross-to-net discounts will stay stable as we go into the fourth quarter, with minimal pricing-driven sales growth. On slide 9, Zoryve's weekly prescriptions, measured on a rolling four-week average, demonstrate continued growth throughout the portfolio. Prescriptions in the quarter exceeded 300,000, setting another all-time high for quarterly demand, with gross growth across every indication and every formulation for Zoryve. As the chart makes clear, Zoryve keeps delivering considerable prescription growth with no indication of slowing. This ongoing demand growth will stay the main driver of Zoryve's revenue expansion through the remainder of the year, and we still anticipate that this trend will accelerate in 2027, reflecting the investments we are making in the business; moving now to slide 10. In September, we introduced the Skin to Believe In campaign together with Simone Biles. The goal of this campaign is to raise awareness of seborrheic dermatitis and eczema and to encourage people affected by these diseases to look into non-steroidal treatment options. Let me begin by saying we could not be more excited to be working with Simone on this important initiative. Simone is genuinely a one-of-a-kind brand ambassador. She is a credible role model, not just because of her extraordinary athletic accomplishments as a once-in-a-generation, world-champion gymnast, but also because of her track record of advocating for awareness and discussion of mental health issues. Beneath all of that is her authentic, approachable, and warm personality. As Frank mentioned earlier, Simone has incorporated both Zoryve foam and cream into her routine and is sharing what that means to her. We believe Simone will deliver broad and deep reach for both disease awareness and Zoryve awareness. The campaign announcement alone produced over 6 billion impressions, which speaks to how wide the impact Simone will have is going to be. Today, when a patient asks their HCP for Zoryve, that request is almost always granted. The honor rate reflects the drug's safe, tolerable profile, its ease of administration, and clinicians' experience with the rapid and robust efficacy and symptom relief it gives patients with inflammatory dermatoses. We'd anticipate that this campaign will boost the count of patients who come in for care and request Zoryve by name. Among dermatology clinicians, the grant rate ought to stay above 90%. Fulfilling our Grow pillar and lifting the new-to-brand prescription rate makes this a key initiative. Past experience likewise shows us that DTC campaigns help HCP awareness and boost patient adherence as well, so there are many advantages this campaign should deliver for the brand and for our business. Skin to Believe In is an omnichannel push. It spans materials aimed at patients and at clinicians, plus advertising and communication. The campaign is already rolling out nationally across a range of channels, yet we expect the effect on demand in prescription volume to become more apparent in early 2027, because awareness and activation for campaigns like this need time before they take hold. Slide 11. As Frank said, Skin to Believe In forms part of a broad and high-impact set of investments we launched in 2026, meant to keep growth going and drive an inflection in Zoryve sales. These initiatives sit in three separate buckets: grow awareness, win share, and enable patient access. Our awareness-building work aims to get patients to seek a medical consultation when signs and symptoms of seborrheic dermatitis, atopic dermatitis, and plaque psoriasis appear, and to consider Zoryve once they pursue treatment; through our Free to Be Me patient awareness campaign, featuring Tori Spelling, her daughter Stella McDermott, and professional golfer Max Homa, we are already generating meaningful patient engagement. That campaign keeps resonating across a wide range of demographics. Adding the Skin to Believe In campaign with Simone Biles will broaden and deepen, in a meaningful way, the engagement and awareness we are creating. Beyond our celebrity endorsement campaigns, we are also putting traditional media tactics to work to reach patients who could benefit from Zoryve awareness; that covers social media deployments, search engine optimization, AI, and similar tools. As we've discussed all year, we've also invested in strengthening our commercial infrastructure via targeted additions to our sales force. Our new dermatology specialty reps have now been in the field for roughly 6 months, and as expected, we've started to see the first growth impact from these reps, shown by weekly demand increases as we closed out the third quarter. In the fourth quarter and as we move into '27 and beyond, we expect this contribution to keep adding to demand growth in an increasing way. Our primary care and pediatric pilot sales force has been in the field since the end of August; they keep raising call activity and building familiarity with their customer base; we're also seeing early signs and signals that primary care and pediatric BNST writers are coming back to Zoryve, along with signs that new writers are prescribing Zoryve. These signals are early, and we're seeing them across the recently created territories. Just to remind everyone, this is a very focused sales force of about 20 representatives, aimed at extremely high-volume PCPs and pediatricians—either those who've previously leaned toward prescribing branded non-steroidal topicals, or those clustered in big metro areas. We expect to start getting, or to see, a clearer read on how this new team is affecting demand as we move into the new year. Like we've mentioned before, we'll be watching demand closely and tracking how this first rollout performs in PCP and pediatrics as we weigh additional steps. As we laid out on the Q2 earnings call, we're also putting measures in place so patients can get Zoryve smoothly and efficiently. Our virtual health platform is built to reach patients wherever they are by tackling the usual obstacles to dermatology care—things like long waits for dermatology appointments, or the lack of specialized dermatology care in certain parts of the country. What we're aiming for with this platform is to help more people get the therapies they need while we keep partnering with dermatology specialists. We think this platform will become more and more important as our Skin to Believe In campaign with Simone Biles builds greater consumer awareness. When patients interact with the campaign, they'll be given ways to easily get to our virtual health platform if they'd like to see a dermatologist online. That will matter a great deal for people seeking a dermatologist consultation for the first time, or for those who run into obstacles accessing specialized dermatology care. We also announced recently a partnership with a leading AI-enabled prescription fulfillment workflow platform, which lets us make patient access to Zoryve more streamlined and systematic once a prescription comes through. This investment is meant to get past the time-intensive process physicians can run into when they prescribe therapy for someone. All together, these efforts represent an important maturing of our mission to create meaningful innovation for people living with chronic skin disease. Millions of people with psoriasis, atopic dermatitis, and seborrheic dermatitis, across all age groups and demographics, ought to be able to benefit from the distinct advantages that targeted topical therapies such as Zoryve offer—especially when compared with the aging topical corticosteroid class. With that, I'll turn the call over to Patrick now for our quarterly R&D update.

Patrick Burnett executive
#21

Thanks, Rob. Good afternoon, everyone. I'm on slide 13. I'd like to give an update on what the R&D team has been doing in support of Grow, Expand, and Build, beginning with our clinical activities supporting the Grow pillar. As Frank said at the top of the call, we're excited to have started a new trial evaluating the use of Zoryve cream 0.3% for treating patients with moderate-to-severe atopic dermatitis; we believe that patients with this more severe burden of disease may benefit from the higher-potency formulation of Zoryve cream; this addition would give HCPs even more flexibility in choosing Zoryve for their AD patients across the spectrum of disease severity. Crucially, among individuals on systemic treatment, competing branded non-steroidal topical products—ruxolitinib included—carry a contraindication, which makes Zoryve a valuable choice for managing lingering disease and flare-ups. Because those in this moderate-to-severe group are the ones most inclined to need biologic or oral medication, this strategy delivers a much-needed alternative, including for patients who later move onto systemic therapy. Enrollment in this study has only just begun, and we anticipate providing additional news as it moves forward. We're also getting ready for the PDUFA action date of February 23, 2027, which applies to the supplemental NDA for Zoryve cream 0.05% in mild-to-moderate atopic dermatitis among infants as young as 3 months. That comes after the approval we received last year for Zoryve cream 0.05% in children with atopic dermatitis down to age 2. As I've said before, I still practice as a dermatologist and actively treat patients, so I understand very well how uniquely difficult it is to manage care for young patient groups—especially the littlest infants and toddlers. Infants between 3 and 24 months don't yet have fully developed skin, and that can mean topical products get absorbed systemically to a greater degree. Beyond that, younger kids with atopic dermatitis tend to have more of their skin surface involved than teens or grown-ups do. Watching a small child struggle with this condition is extremely difficult for moms, dads, and other caregivers, and their worry about possibly harmful effects from topical steroids makes matters worse. Given all of this, these young patients are among those with the most pressing need for a non-steroidal topical that is safe, works well, and is tolerated easily. We're thrilled that we're about to deliver the innovation of Zoryve to these children along with their parents and caregivers. Assuming it gets the green light as expected, that would mark an especially satisfying achievement for our team; meanwhile, enrollment is ongoing in the pair of studies we started during the second quarter. The initial one, INTEGUMENT-ITCH, is being run in adults so we can more clearly define how Zoryve affects pruritus—that is, itch. To recap, we launched that study on the strength of persuasive findings from INTEGUMENT-INFANT, which demonstrated itch reductions beginning 10 minutes after the initial application. The second study looks at Zoryve's impact on nail psoriasis—a form of plaque psoriasis that is famously difficult to manage and often fails to respond to systemic therapy; via case reports, as noted earlier, we've seen some promising signals of Zoryve's effectiveness in nail psoriasis, and we're keen to dig deeper into the chance to support this group of psoriasis patients. Moving now to our clinical advances under the Expand pillar, which spans efforts focused on broadening the Zoryve franchise to serve individuals with other chronic inflammatory conditions past the indications that are approved today. Building on what Frank said, we're still on schedule to deliver data from our vitiligo proof-of-concept study during this quarter, along with a call on moving that program forward. I'll go into more detail soon regarding why we're interested in vitiligo. In addition, enrollment is ongoing in our Phase 2 proof-of-concept studies of Zoryve foam among hidradenitis suppurativa patients, and we anticipate sharing those trial results together with an advancement decision for that program in the first quarter of 2027. For hidradenitis suppurativa, Zoryve has the potential to be an important and highly differentiated therapeutic choice. As of right now, HS patients have no topical treatments cleared by the FDA, and milder cases have nothing either, whereas those with more severe disease usually depend on systemic therapies. If a topical product could be used either alone or alongside systemic therapy with no restrictions, that would hand patients and their clinicians a valuable treatment choice. Because HS tends to show up in hair-bearing regions like the groin and axilla, our foam formulation might deliver a substantial extra advantage for patients. On a separate note, we are getting ready to open enrollment in a study looking at how Zoryve cream 0.3% affects cutaneous adverse events among cancer patients undergoing PD-1 or PD-L1 checkpoint inhibitor treatment. Up to fifty percent of people getting these life-saving therapies experience such side effects, and those effects frequently disrupt their cancer treatment. Should Zoryve prove able to control these treatment-linked dermatoses effectively — as the case reports we have observed indicate — it could assist cancer patients in remaining on their prescribed regimen. This study offers yet another notable illustration of how broadly Zoryve might be applied across inflammatory skin conditions. And now, last, our Build pillar and ARQ-234. That is our innovative CD200R biologic being developed for atopic dermatitis. We have moved it into the final single SAD cohort and started enrolling atopic patients in the multiple ascending dose portion of the study. We're glad to report that enrollment is complete across every single ascending dose portion, and the safety profile that's starting to emerge gives us encouragement. As we said before, once the MAD part of the study wraps up, we intend to launch a small proof-of-concept cohort, and we won't disclose findings from this trial until that proof of concept has finished. We're eager to share additional data down the road on what ARQ-234 may offer. Let's turn to slide 14. As we approach near-term data from the initial proof-of-concept trials exploring Zoryve's use in additional indications, I'd like to review some important aspects of its pleiotropic mechanism of action that shed light on why we're evaluating such a broad array of potential applications. Zoryve acts through inhibition of phosphodiesterase-4, or PDE4 — an enzyme found widely in cells throughout the human body, where it governs cyclic adenosine monophosphate, or cyclic AMP, an intracellular messenger with functions that differ depending on cell type. Traditionally, PDE4 inhibitors have been viewed as agents that modulate the immune system, and in fact, inside immune cells, PDE4 blockade influences multiple biological pathways associated with immune-mediated inflammatory skin conditions. More specifically, PDE4 inhibition lowers expression of several key pro-inflammatory cytokines, such as interferon gamma, type 1 interferon alpha, TNF-alpha, and IL-4, 6, 17, and 23 — spanning signaling through Th1, Th2, and Th17 immune-mediated responses. Yet PDE4 inhibition does much more than modulate immunity. Take sensory neuron activation, for instance — PDE4 is involved there as well. Blocking PDE4 appears to act directly on the itch sensation, which fits with the fast and marked itch relief seen with Zoryve across multiple studies. As I noted, we are working to better characterize how quickly Zoryve affects pruritus in atopic dermatitis via the INTEGUMENT-ITCH trial, which is enrolling now.

Patrick Burnett executive
#22

Inhibiting PDE4 likewise brings keratinocyte activation and differentiation back to normal, and that can help lessen the epidermal barrier dysfunction seen in a lot of inflammatory dermatoses. Beyond that, PDE4 inhibition as a class—and roflumilast in particular—has shown anti-fibrotic activity across a range of diseases, among them lung fibrosis and keloids. Several inflammatory skin diseases carry fibrotic elements, hidradenitis suppurativa included, and we keep assessing Zoryve for use in that indication. That piece of roflumilast's pleiotropic mechanism of action might turn out to matter a great deal. The various parts of this mechanism laid out on this slide, together with the neuronal itch mechanism I went through earlier, were covered in a recent publication by Dr. As Raj Chovatiya noted in the International Journal of Dermatology, for any particular indication, those distinct components of the PDE4 mechanism of action can matter to varying degrees. Take HS: in addition to bringing fibrosis under control, modulating neuronal signaling matters, as does suppressing the core inflammatory pathways driving disease activity. About half of HS patients experience itch, while 60% describe their pain as moderate to severe. Addressing those symptoms directly, instead of solely via inflammation modulation, may offer an advantage. TNF-alpha and IL-17 feature in the inflammatory profile of HS, and multiple biologic therapies have gained approval in that area. Those pathways are clearly connected to PDE4 inhibition and play a role in how effectively Zoryve performs in approved indications like psoriasis and seborrheic dermatitis. Taken together, this appears to make Zoryve, and the PDE4 mechanism of inter-PDE4 inhibition, an especially strong fit for hidradenitis suppurativa—a condition that severely impacts quality of life and has traditionally been difficult to treat. Lastly, moving to vitiligo, PDE4 inhibition promotes melanocyte proliferation, increases melanocytic gene and protein expression, and protects melanocytes from apoptosis. When you put those effects together with Zoryve's ability to fight inflammation, you get a completely different approach to treating vitiligo—one that may be able to tackle the disease from both directions at once: extinguishing the fire by lowering the inflammatory signals responsible for destroying melanocytes, and at the same time rebuilding the structure by helping melanocytes recover and repigment. This mechanistic reasoning about what Zoryve could potentially accomplish in vitiligo is among the factors behind our interest in running clinical evaluations of Zoryve for that disease. A further factor is the clinical signals that have come in from the field. I'm now on slide 15. During last fall's R&D event, we explained that a substantial collection of case reports from clinicians who have prescribed Zoryve for various inflammatory dermatoses outside our currently approved indications serves as our guide when exploring new indications. We have found it encouraging that several clinicians pursued vitiligo as a novel use for Zoryve, especially in hard-to-treat vitiligo presentations, and reported a signal of efficacy—repigmentation following an earlier inadequate response to other therapies—with no adverse events reported. Today I'd like to draw attention to a case involving a 37-year-old male patient in Canada that was published recently in the Journal of Drugs in Dermatology. As you can see, this patient with long-standing, hard-to-treat vitiligo experienced dramatic repigmentation on the face at 4 months, which became even more pronounced and persisted at 7 months when Zoryve cream was combined with narrowband ultraviolet B therapy. Such a case study illustrates clearly why we have felt motivated to investigate Zoryve further in vitiligo. Before continuing, I want to remind you of several details regarding our ongoing Phase 2 proof-of-concept trial of Zoryve foam 0.3% for vitiligo treatment. This open-label, single-center proof-of-concept study aims to establish whether the clinical signal observed with Zoryve justifies moving forward into Phase 3 development. We've now enrolled all 20 patients we were targeting. The main measure we're looking at is how many patients show a 50% improvement on their Facial Vitiligo Area and Severity Index score by week 24. As I said earlier, we expect to have those results during the fourth quarter. If efficacy comes in similar to what's already approved, that could be enough to justify moving the program ahead, especially given Zoryve's strong therapeutic profile — and if we see any kind of efficacy separation, that would set up a potential best-in-class profile. Naturally, whether we proceed and in what manner will hinge on the Phase 2 data, and any registrational effort would require us to align with regulatory authorities on a suitable Phase 3 design. As we move the vitiligo and HS trials forward, we're also continuing to assess other conditions for comparable proof-of-concept work, and we'll update investors whenever we choose to launch further such trials. I'll now hand things to Latha for the financial results.

Latha Vairavan executive
#23

Thanks, Patrick, and good afternoon, everyone. I'm on slide 17. In the third quarter, net product revenues came in at $143.9 million, an increase of 45% over Q3 of 2025. That year-over-year growth was mainly fueled by higher patient demand, along with quite modest gains in gross-to-net sales deductions. Versus Q2 2026, sales rose 11%, again driven by greater patient demand, while gross-to-net stayed steady in the 50s, in line with the prior quarter. Cost of sales for the third quarter totaled $12.5 million, versus $8.7 million in the third quarter of 2025, largely because of growing Zoryve sales volume. R&D expenses for the third quarter of 2026 were $22.4 million, compared with $19.6 million in the corresponding period of 2025. That year-over-year rise reflected higher clinical development expenses for ARQ-234. SG&A expenses were $99.6 million for the second quarter of 2026, compared to $62.4 million in the same period last year. I apologize—I meant the third quarter of 2026. That's up 60%, driven by greater media spend, mainly in support of the Skin to Believe In campaign, plus higher personnel-related costs from our sales force expansion. Turning to the fourth quarter, we expect expenses to stay at this level as we keep investing in commercialization efforts for Zoryve to lay a foundation for a sales inflection in 2027 while we continue advancing our innovative pipeline; we generated net income of $8.8 million for the quarter, compared with net income of $7.4 million in the same period of 2025. Moving to slide 18. We closed the quarter with cash and marketable securities of $259.8 million, as we generated positive cash flow from operating activities of $18.9 million for the period. We expect to keep positive cash flow through the end of the year. As we've discussed throughout this call, we plan to reinvest the capital we generate back into our business to accelerate growth in 2027 and beyond, though we will remain careful stewards of our cash and shareholder equity. We have total debt of $109.4 million. As Frank noted in his opening remarks, given the strength of our Q3 results, we are raising our net revenue guidance to $535 million to $545 million, up from the previous range of $525 million to $540 million. With that, I'll turn the call back to Frank for final thoughts.

Frank Watanabe executive
#24

Thank you, Latha, and once more I appreciate everyone being with us today and for the ongoing interest you show in Arcutis. As you can tell, we keep delivering meaningful advancement as we execute across each of the three pillars of our Grow, Expand, Build strategy. We feel proud of every achievement we have secured so far on behalf of patients, and we are tremendously enthusiastic about the numerous potential chances ahead to broaden our reach and deepen our impact going forward. As ever, I want to express gratitude to our team for their unwavering dedication, which underpins all of the mission-driven progress we make and puts us in position to create enduring value for shareholders; with that said, we will now take questions on the call.

Seamus Fernandez analyst
#25

Oh, thank you for taking the questions. I have two quick ones. First, regarding how the business is trending, the team keeps saying that growth in 2027 actually accelerates compared with 2026. Relative to where consensus sits right now, that implies a fairly impressive path. I was hoping you could help frame that acceleration for us, and if I have that wrong, please correct me. Then the second one is for Patrick, about the opportunities ahead, hidradenitis, all of the other possible indications, vitiligo in particular, we saw and we do see extremely high rates of persistence as it relates to vitiligo treatment. I'd just like to get a clearer picture on the commercial side, and where you'd actually expect the persistence to show up. If vitiligo does end up succeeding and moves into Phase 3 and eventually gets approved, how much of an increase in the number of tubes per patient do you think there could potentially be, relative to the utilization we're seeing today? Thanks so much.

Frank Watanabe executive
#26

Hi, Seamus. It's always great to hear from you. Just briefly on your question about the sales trajectory, look, I think all of you can see the underlying strength of the business as it currently stands. When you consider how large this market opportunity is—something we keep discussing—along with the consistent movement by dermatologists toward advanced topical therapies, and then layer on the strategic investments we're continuing to make in the business, which we outlined today, we're genuinely enthusiastic about our capacity to maintain or perhaps even speed up our growth going forward. I suspect I'd catch some trouble if I went too deep into the details, so I'm going to hand it over to Latha, who can perhaps shed a bit more light on that, and then Patrick can address your question regarding some of the new indications.

Latha Vairavan executive
#27

Hey Seamus, hope all is well with you. I think I can break this down into three points. First, we delivered a robust quarter, and we raised our guidance — which really serves as evidence of the momentum we're carrying as we head into Q4 and wrap up the year, especially since Q4 has consistently been our best quarter. Second, staying consistent with what I've said before, we intend to strengthen our growth and turn our 2027 net sales upward, since that's the route to the peak sales figures we've shared publicly, and every investment we're making is aimed at that inflection point. Now is not the moment for me to offer a cautious guide. I'm aware we did that a year ago because it was our first time doing so — you'll need to wait until we finish the year and move into 2027. I'll pass it to Patrick to take your second question.

Patrick Burnett executive
#28

Seamus, I think you're highlighting some genuinely fascinating features of these two diseases, particularly when you set them against psoriasis, seb derm, and atopic dermatitis, correct? With those conditions, patients usually treat and get the disease under control; we conducted some fairly brief trials in those indications: 4 weeks for atopic dermatitis, 8 weeks otherwise. After it's controlled, patients might treat intermittently, or a couple times a week, or perhaps pause treatment briefly and then restart. What I'm hearing from you is that especially with vitiligo — I brought up a 24-week endpoint — and I'd also include hidradenitis suppurativa, these are diseases that historically, just given their very nature, tend to require a long time to bring under control; on top of that, the treatments are frequently applied daily for a year or more. That differs somewhat, I believe, from what we've observed in certain other indications we hold approvals for at present. Exactly how that would play out in terms of tube usage over time — I think we'll need a bit of time to work through that; it will be affected by the body surface area of the typical patient out there. I believe sorting that out will require somewhat more time, but I think you're pointing to a significant distinction between these two indications specifically and some of those we're approved for.

Seamus Fernandez analyst
#29

Thank you very much.

Steve Seedhouse analyst
#30

Good afternoon, and thanks a lot for the question. Congratulations on the strong growth. I'd like to zero in on the R&D side with a couple of questions, and starting by digging into that vitiligo case report on slide 15, it's quite tantalizing a response — possibly more impressive, in fact, than any of the others published so far. I'm curious whether anything about the case, the patient's history, or anything else stands out to you as perhaps explaining why this was such a good responder, and should we be expecting responses like this in your open-label trial, or would you rather not set that expectation? So once a patient reaches full clearance like that, do they stay on the therapy? From what we can see, they were still on it between months four and seven. Is there a rationale for just carrying on with treatment with no end point, or does it get stopped at some stage assuming the response is more or less complete?

Patrick Burnett executive
#31

Right. This is a fascinating instance, and I believe that's part of what makes case reports tricky; that's the reason we chose to run our own study, even though it's a fairly small, open-label trial, because in that setting you gain a sense of the denominator, since case reports can showcase some of the most striking responses. Even so, recognizing that point, I'd say the fact that this individual ended up showing what is genuinely a quite remarkable response — something I'd describe as fairly unusual across my whole career of treating vitiligo patients — isn't the kind of thing you'd expect from many of the treatments available today. To me it's very fascinating. Since it's just one case report, that's the reason we're digging a bit deeper. Narrowband UVB, though, is something I'd describe as a treatment element that has long been a staple for a lot of patients; we actually advise people to head outdoors and soak up some ultraviolet light from the sun when they live somewhere that allows it and the season fits. Hearing a dermatologist suggest that someone go outside and expose themselves to the sun is quite uncommon. My sense is that this likely isn't a major confounder in this case, simply because we all grasp fairly well how that level of efficacy appears, and it doesn't resemble what this patient experienced. Only time will reveal the answer. I don’t want to make that the standard for how every patient reacts to Zoryve. As we all know, whenever you treat patients, responses tend to fall along a range. What you’re also getting at regarding how long treatment lasts—we recently had a very productive discussion with vitiligo specialists, with our team helping us prepare for upcoming trials. Their guidance identifies this as essentially a core component of the therapy: if a patient responds well, the plan is to continue treatment for 4 months, specifically to confirm that no residual inflammation remains in the skin. The question of when to stop is something the field is actively debating at present. My sense is that the preference leans toward keeping patients on long-term therapy, even when their response is really good, and then perhaps tapering gradually as time goes on — but you certainly would not halt treatment for a patient responding greatly and then simply watch and wait immediately. That is not the direction the field is heading.

Frank Watanabe executive
#32

Steve, maybe I can tack on a couple of extra points regarding this specific case—and I want to be fully clear upfront that, unlike Patrick, I'm not a dermatologist. Still, I think it's genuinely worth noting that this patient had tried topical steroids and topical calcineurin inhibitors without success prior to experiencing this striking response on Zoryve, and that, to me, only heightens our enthusiasm about the vitiligo data we'll be seeing. And then the second thing that really jumps out about this case is how quickly the response came—and I think those two elements might tie back to what Patrick mentioned regarding the pleiotropic mechanism of PDE4 inhibition in vitiligo, as opposed to the conventional approach that is purely anti-inflammatory, which is what steroids and the other topical therapies have actually been targeting in vitiligo.

Steve Seedhouse analyst
#33

Obviously looking forward to seeing your full dataset soon. On a separate note, I wanted to follow up on something mentioned in the prepared remarks regarding BD or external innovation. It sounded like you noted some general interest there, along with possibly some goals about its scope, and I just wanted to see whether you could expand on your thinking — for instance, what's your level of motivation to acquire any additional asset or assets, what deal size or development stage falls within your scope, and what timing you envision for anything along those lines? Thanks so much.

Frank Watanabe executive
#34

Sure. Thanks for that question, Steve. I think we've talked about this with investors several times before. Now, we're definitely keen to bring additional products into our portfolio. Our development team, I feel, has demonstrated remarkable abilities—seven FDA approvals, all delivered on schedule over the past four years, with an eighth coming up soon, plus nine successful Phase 3 trials. That's a strong track record for any large company, never mind a small one. They've clearly shown they can execute on clinical development programs and manufacturing. Because we aren't halting Zoryve work—just easing off how quickly those programs advance while we wrap up every indication already under way—I believe we have room to take on additional efforts. That's one side of it. On the other side, considering everything already occupying us—inline Zoryve, expanding Zoryve's lifecycle, and ARQ-234—my prior stance stands and I still hold to it: business development is a nice-to-have rather than a must-have for this company. That leaves us, I'd say, in an enviable spot where doing business development is simply our choice, correct? My view is that once a company reaches the point where business development becomes necessary just to keep going, poor choices tend to follow. Our team is excellent, and at any given moment it is probably reviewing around a dozen assets. Over the past 10 years we have examined something like 350 or more assets, and only two have been purchased. That gives you some sense of how demanding our standard is, and our approach to assessing assets will stay highly disciplined. I have also told the Street that, in my opinion, we are seeing more deal flow. Whether that reflects the broader funding climate or stems from us being viewed as a go-to partner for those seeking to license their asset, I can't say for sure. Opportunities are certainly abundant on our end; the real question is whether we identify a prospect where we believe shareholder value can be created. If we do, we'll act—and if not, we won't squander shareholder money.

Steve Seedhouse analyst
#35

Okay. Many thanks, Frank and team, and congratulations as well to Rob on the new position. Thanks.

Andrew Tsai analyst
#36

Hi there, good afternoon. Appreciate all the detail today. Perhaps the first one, following up on BD, since, Frank, you described BD as nice-to-have rather than must-have. My question: otherwise, what are you going to do with all that cash you'll be accumulating over the coming few quarters? And second, for vitiligo and HS coming up, once you share the top-line datasets, how detailed will each program's dataset be? Beyond giving us the go/no-go decision, do you intend to share a rough Phase 3 design when the top line comes out, or does that update arrive later in 2027, after FDA discussions? Thank you.

Frank Watanabe executive
#37

Thanks, Andrew. Two excellent questions. But I'm going to hand both of them off. Latha, could you perhaps take the question about use of capital going forward, and then, Patrick, could you maybe weigh in on what to expect regarding the top-line data from vitiligo and HS.

Latha Vairavan executive
#38

Yes. Hi, Andrew. To address what you asked first: yes, as we keep building leverage, we're going to put money into the business. As I mentioned, and I believe we've said this repeatedly, the big change in operational leverage is going to arrive in the later portion of '27 and on into '28. Up to that time, the focus will be investing in our business so that we can bend the growth curve upward. Beyond that, once we've built substantial leverage, as you noted, and a great deal of cash, to use your words, then if a BD still hasn't happened, I'd say your question is a reasonable one. At that stage, I believe we'll locate the appropriate asset that suits our pipeline. I think we're largely focused on assets in late Phase 2 and early Phase 3. Right now, the leverage is meant for investment in the business to bend the trend, and once that takes hold, we'll redirect it toward BD. I think over the long run, if by '29 I'm sitting on leverage and no BD has been done, then we'll have that conversation.

Patrick Burnett executive
#39

I can take the vitiligo question. Yeah. What you should expect is that we'd walk through this study and then discuss our rationale for moving forward — we'd lay out the data and the level of detail that I believe helps you see why we'd advance this program and how we reached that decision, along with the data backing it up. In a study of 20 patients like this one, we've provided some clinical context drawn from case reports in the field, which really matter for helping us grasp the possible clinical profile, and then we'd discuss how this trial sharpened our understanding of that profile. We would definitely outline what a Phase 3 program for this indication would look like. As you mentioned, the final specifics of that program will require further engagement with the FDA to ensure we're all aligned on getting the product registered should we advance it.

Andrew Tsai analyst
#40

All right, thanks a lot.

Tyler Van Buren analyst
#41

Yikanna here, filling in for Tyler. Congratulations, everyone, on a fantastic quarter. I've got just one quick question. You mentioned that you're moving forward with the 0.3% cream in moderate-to-severe AD. I'm curious about your reasoning for choosing that SKU, and how you see a topical fitting into that treatment landscape, plus what kind of opportunity you believe exists there?

Frank Watanabe executive
#42

Absolutely. Patrick, would you like to handle that one as well?

Patrick Burnett executive
#43

Certainly. This program has me genuinely enthusiastic, since what it enables us to accomplish is, in a sense, to bracket things—if you pull back for a moment and consider our position in AD, once we (assuming approval arrives) have the 3 to 24 month indication with the 0.05% after February of next year, and later add this product, we would truly be bracketing an AD patient no matter what their age, starting at 3 months—the earliest onset for someone with atopic dermatitis—across their whole life. We have also discussed bracketing the full severity spectrum: mild-to-moderate as well as moderate-to-severe. The reason we selected 0.3% is that it is the strongest strength we have approved, and we believe it is likely the strongest strength capable of delivering any added benefit in those patients sitting at the more severe end; bear in mind that mild-to-moderate is already approved, and what we are now discussing is moderate-to-severe. You might argue that we are merely adding severe patients, and to some degree that holds true, yet healthcare providers tend to view these as two distinct groups that overlap in the middle. Once we begin discussing moderate-to-severe patients, these are individuals for whom you might expect that eventually a systemic therapy will probably be needed. What healthcare providers have told us is that Zoryve plays a genuinely important part in that decision-making. Frequently, patients receive Zoryve to see whether a systemic therapy can be avoided. We have heard case reports and anecdotal accounts in which paperwork had even been started to place a patient on a systemic, only to find that progressing isn't actually necessary given the response observed. Generating data specifically at the higher strength genuinely creates an opportunity to capture every possible atopic dermatitis patient out there who is appropriate for treatment with Zoryve, and additionally to have them potentially stay on it should they need to move up to a systemic therapy, since we know that fits well with the approved Zoryve indications, where concomitant use alongside biologics or oral treatments is not excluded.

Tyler Van Buren analyst
#44

Thanks.

Mike Ulz analyst
#45

Hey, everyone. This is Parthron speaking on behalf of Mike. Appreciate you letting us ask. To build on that moderate-to-severe AD opportunity, do you view it as a crucial population for reaching the peak sales figure you shared before? And regarding next year with the infant AD population, what's your thinking on growth there as we move later into next year?

Frank Watanabe executive
#46

Yeah. Rob, would you like to handle that one?

Rob Lisicky analyst
#47

Yes. On the first part of your question, the idea is essentially from cradle to cane—for any patient, at any moment, you have a choice for that patient with a topical, with or without a systemic, particularly once you start getting into the severe range. For the infant, the 3 to 24, we think there's a chance for us to unlock meaningful potential and value in that space. If you look at that category, claims data shows there are over a million claims for patients aged 3 to 24. One reason we pursued the PCP and Peds expansion, along with the thinking behind it, was to bring in some of those ancillary treaters — largely pediatricians plus a portion of PCPs; in our view, combining the product with our sales force leaves us uniquely positioned to seize that opportunity. We further believe we can show a distinct benefit for these patients that will carry over to patients older than 24 months too.

Mike Ulz analyst
#48

Great. Thank you.

Douglas Tsao analyst
#49

Hi. Good afternoon. Thanks for taking the questions. I'm just wondering whether you can give us some sense of the recent prescription trends, since following last winter's approval of the cream we enjoyed a decent lift; then, as I know is usual, there's some seasonality early in the year, but after that script growth appeared fairly flat, and then in the past few weeks it has really accelerated again. I'd just like to know if you can shed any light on what has been driving that since the summer.

Frank Watanabe executive
#50

Yeah. Rob, do you want to handle that one as well? Sorry for putting you on the spot.

Rob Lisicky analyst
#51

Yes, thanks for asking. There are a couple of things you're getting at there. Seasonality plays a role, and the timing of when it kicks in can shift somewhat from quarter to quarter or year to year, depending on when holidays and vacations land, that sort of thing. Another piece, I think, is a few of the early indicators I brought up around the derm expansion. What the data shows me is that once targeting and frequency reach the level we consider right, that business grows extremely fast and dramatically; we began seeing that in September, really for the first time. We've seen some gains in patient adherence too. It's those factors combined where some of those key investments are beginning to pay off, and the more experience physicians gain with the product, the longer they tend to keep patients on it.

Frank Watanabe executive
#52

Let me add just one more thought here—Rob is relatively new to the team, so he doesn't have the history. This question comes up now and then. If you step back and consider the trajectory of this product, certainly from the foam launch in early '24, it's truly been a very strong, sustained growth trend. You do get week-to-week variability. I've said to you folks before that the investment community really should not be watching weeklies, correct? They're simply too noisy. At a minimum, rolling four-week averages are what you ought to be looking at. Looking at those rolling four-week averages, a very clear and consistent growth trend shows up. Occasionally we hear this question about deceleration. In the data, I don't see it. Look too closely at these narrow slices of data and you can miss the forest for the trees. The trend has consistently been up and to the right, and we expect that to keep going.

Douglas Tsao analyst
#53

Frank, and I believe that's a valid observation. I suppose from my perspective, what was really so remarkable is simply what we've observed ever since September 1st, correct, where, and I think when speaking with investors, it was kind of like, oh gee, what's happening here? That's kind of what gave rise to the question. Thank you.

Frank Watanabe executive
#54

Definitely. Definitely, and I think, regarding Rob's point, we've been making investments all through 2026 and generating growth for the business. I think we established the expectation that a lot of these would not produce large returns in 2026. I think we'll witness much of the effect in 2027; we are beginning to witness the effect of some of those investments, and as Rob said, I think the derm expansion is one where we have enough time behind us that we likely are beginning to witness the leading edge of that impact, certainly.

Douglas Tsao analyst
#55

You also brought up some improvement in adherence, and I'm just wondering what initiatives are behind that gain. Thank you.

Frank Watanabe executive
#56

Sure. Rob?

Rob Lisicky analyst
#57

We work with a range of specialty pharmacy providers, and those providers may send reminders out to patients. Another area where we've placed substantial emphasis operationally is this: whenever a physician — or an NP or a PA — writes a prescription for Zoryve, we strongly encourage that prescriber to add refills. That approach has been in place, I believe, since the beginning of the year. Those are, I'd say, two fairly simple tactics we've been able to deploy to assist and to make a difference in some of what you're likely alluding to that showed up in September.

Douglas Tsao analyst
#58

Great. Thank you very much.

Serge Belanger analyst
#59

Hi. Good evening, everyone. John here, filling in for Serge this evening. We appreciate you taking our question. I was hoping to ask about your expectations for Zoryve's growth in 2027. You have several initiatives that you've started to set in motion, including the dermatology sales force expansion, the new PCP team, and the virtual health platform that has been running for the last few months. I know it's still early, but I'm curious whether you can share any anecdotal sense of how these programs are launching in '26, and then as we look toward 2027, which of these three levers do you view as the main driver for either sustaining Zoryve's growth or even turning it upward? Thanks.

Frank Watanabe executive
#60

Wow, Rob, you're certainly earning your keep today. Would you like to handle that one?

Rob Lisicky analyst
#61

Let me address the telehealth component; over the product's lifecycle, we view it as a key initiative. You're witnessing growing demand for telehealth driven by specialty access, by remoteness, and by the broader healthcare system as a whole. It's still early, but what we observe is that once a qualified patient enters the system, the conversion rate is extremely high. In fact, it couldn't be much higher. As we scale this, I think the difficulty lies in continuing to grow the volume of qualified traffic reaching the telehealth site. When we discuss all the various tactics and investments we're making, there's sometimes a habit of examining these individually to grasp their impact; we consider them together, correct? How does the Simone Biles campaign assist in generating traffic for telehealth? How does our work with Tori Spelling and her daughter, or Max Homa, assist in generating traffic? Together, all of these are generating traffic there, but it's genuinely early to determine whether to essentially declare success. What I observe today is that when good, qualified patients enter that site, our conversion rate is extremely high, and we'll keep driving that throughout 2027.

Rich Law analyst
#62

Hi, everyone. Congratulations on the progress achieved so far. I'd like to follow up regarding the vitiligo case study. The disease pathways are quite highly heterogeneous and complex. Do you think there are specific drivers where Zoryve might not be effective? Going back to that case study, it appears very impressive, but have you also come across other case studies involving patients with concurrent vitiligo and AD or psoriasis whose vitiligo symptoms didn't improve?

Frank Watanabe executive
#63

Yes. Rob, at last you get a pass. Patrick, would you like to handle that one?

Patrick Burnett executive
#64

Absolutely. I concur that heterogeneity does exist within the vitiligo population. There's no question about it; we likely aren't hearing about those patients who are receiving treatment and failing to respond. Certainly, many of those individuals never end up in a case report. It's hard for me to really comment on that. If I step back and consider the mechanism, and I realized as I was reading out all the various pathways targeted from an immune standpoint by PDE4 — and roflumilast and Zoryve as a result — just how ridiculous it was, it truly is striking that this is immune-modulating yet not immunosuppressive, even though it touches all these different components. While some heterogeneity exists within the vitiligo population, and we'll certainly learn more about it as we expand into larger trials where I have data to speak about it specifically, what we haven't observed in vitiligo is a clear responder/non-responder population based on aspects of the disease. In fact, I mentioned this engagement we just had with some key thought leaders, and they told us that even duration of disease — something that has emerged in some of these autoimmune conditions as a real predictor of possible treatment response — may not, in their minds, actually be that good a predictor of whether a patient will respond. I think we'll just have to learn, but it's something I'll definitely keep my eye on.

Rich Law analyst
#65

Great. Thank you.

Frank Watanabe executive
#66

Again, we truly appreciate you guys joining us and all the excellent questions you send our way; we're looking forward to bringing you all up to date on the full-year 2026 in just a few months. Hope everybody has a wonderful holiday, and we look forward to speaking with you then. Thanks very much. Bye-bye.

Operator operator
#67

This concludes today's conference call. Thank you for participating, and you may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Arcutis Biotherapeutics, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Arcutis Biotherapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.